BioMarin Pharmaceutical (BMRN) : Rhenman Partners Asset Management Ab scooped up 72,000 additional shares in BioMarin Pharmaceutical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 19, 2016. The investment management firm now holds a total of 190,000 shares of BioMarin Pharmaceutical which is valued at $17,822,000.BioMarin Pharmaceutical makes up approximately 3.23% of Rhenman Partners Asset Management Ab’s portfolio.
BioMarin Pharmaceutical opened for trading at $91.98 and hit $94.08 on the upside on Friday, eventually ending the session at $93.8, with a gain of 1.97% or 1.81 points. The heightened volatility saw the trading volume jump to 25,49,652 shares. Company has a market cap of $15,157 M.
Other Hedge Funds, Including , Crossvault Capital Management boosted its stake in BMRN in the latest quarter, The investment management firm added 3,740 additional shares and now holds a total of 18,145 shares of BioMarin Pharmaceutical which is valued at $1,702,001. BioMarin Pharmaceutical makes up approx 1.24% of Crossvault Capital Management’s portfolio. Santa Fe Partners added BMRN to its portfolio by purchasing 13,930 company shares during the most recent quarter which is valued at $1,208,428. BioMarin Pharmaceutical makes up approx 0.20% of Santa Fe Partners’s portfolio. Integrated Investment Consultants added BMRN to its portfolio by purchasing 613 company shares during the most recent quarter which is valued at $53,178. BioMarin Pharmaceutical makes up approx 0.03% of Integrated Investment Consultants’s portfolio.Eagle Asset Management Inc reduced its stake in BMRN by selling 1,067 shares or 0.61% in the most recent quarter. The Hedge Fund company now holds 172,623 shares of BMRN which is valued at $14,362,234. BioMarin Pharmaceutical makes up approx 0.10% of Eagle Asset Management Inc’s portfolio.
On the company’s financial health, BioMarin Pharmaceutical reported $0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.55 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $+0.94. The company had revenue of $227.90 million for the quarter, compared to analysts expectations of $224.71 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Many Wall Street Analysts have commented on BioMarin Pharmaceutical. Robert W. Baird Upgraded BioMarin Pharmaceutical on Mar 8, 2016 to ” Outperform”, Price Target of the shares are set at $110.Company shares were Reiterated by Stifel on Mar 3, 2016 to “Buy”, Firm has raised the Price Target to $ 107 from a previous price target of $105 .Shares were Reiterated by Wedbush on Feb 29, 2016 to “Neutral” and Lowered the Price Target to $ 105 from a previous price target of $117 .
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).